Locus Biosciences has raised $19 million in Series A funding led by ARTIS Ventures of San Francisco, California. Other major investors included Tencent Holdings of China and Abstract Ventures, also based in San Francisco. Funds will be used to file the company’s first investigational drug with the FDA and to conduct a clinical trial with humans. Locus claims to be the only company using CRISPR-Cas3 gene editing to destroy antibiotic-resistant microbes once they have infected a cell. Whereas CRISPR-Cas9 is popularly developed for gene editing and repair, Cas3, which is too large to enter human cells, disrupts the replication of bacteria. The research would improve medical outcomes because, according to the Centers for Disease Control, over half of antibiotics prescriptions are inappropriate, killing good bacteria along with the bad and thus weakening the natural immune system while incubating cure-resistant mutations for invading microbes. Locus spun off from North Carolina State University in 2015 with loans from the Biotechnology Center and NCBiotech.